CN
PHR1447
应用筛选条件
关键词:'PHR1447'
显示 1-30 共 36 条结果 关于 "PHR1447" 范围 论文
Jing Dai et al.
Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 12(2), 128-131 (2010-03-05)
Levetiracetam has been widely used for childhood epilepsy, but there is no high quality evidence to support its use. This study performed a systematic review to evaluate the effectiveness and safety of levetiracetam therapy for childhood epilepsy. The papers related
[Levetiracetam (keppra) in epileptology].
V V Kalinin
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 107(3), 74-77 (2008-08-08)
Karine Leclercq et al.
Epilepsia, 56(2), 310-318 (2014-12-20)
The 6 Hz model of focal seizures has been increasingly used to identify anticonvulsant compounds with potential activity against therapy-resistant epilepsy, but the protective response to anticonvulsants in this model could be dependent on experimental conditions and selection of mouse
Laxmikant S Deshpande et al.
Neurotoxicology, 44, 17-26 (2014-05-03)
Paraoxon (POX) is an active metabolite of organophosphate (OP) pesticide parathion that has been weaponized and used against civilian populations. Exposure to POX produces high mortality. OP poisoning is often associated with chronic neurological disorders. In this study, we optimize
Katherine A Lyseng-Williamson
Drugs, 71(4), 489-514 (2011-03-15)
Levetiracetam (Keppra®, E Keppra®) is an established second-generation antiepileptic drug (AED). Worldwide, levetiracetam is most commonly approved as adjunctive treatment of partial onset seizures with or without secondary generalization; other approved indications include monotherapy treatment of partial onset seizures with
Evren Burakgazi et al.
Clinical EEG and neuroscience, 45(2), 89-91 (2013-12-21)
This study reviews our experience with the safety and tolerability of levetiracetam (LVM) with different methods of intravenous administration in intensive care unit (ICU) patients. We used retrospective chart review to identify 33 ICU patients who received intravenous LVM for
Gaetano Zaccara et al.
Epilepsia, 55(7), 1048-1057 (2014-06-07)
To assess the comparative efficacy and safety of pregabalin and levetiracetam for the reduction of seizure frequency in patients with partial seizures. This was a randomized, double-blind, flexible-dose, parallel-group noninferiority study of pregabalin and levetiracetam (randomized 1:1) as adjunctive treatment
Justin B Usery et al.
Journal of neuro-oncology, 99(2), 251-260 (2010-02-11)
To determine the safety and tolerability of IV and oral levetiracetam monotherapy for seizures in brain tumor patients following resection. Brain tumor patients undergoing neurosurgery with >or=1 seizure within the preceding month prior to surgery were enrolled to receive intravenous
[Pharmacology and clinical results of levetiracetam (E Keppra(®) Tablets), a new antiepileptic drug].
Yutaka Ishii et al.
Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 137(2), 95-102 (2011-02-16)
Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam.
Rafal M Kaminski et al.
Epilepsia, 50(3), 387-397 (2008-07-17)
Levetiracetam (Keppra) is an antiepileptic drug (AED) characterized by a novel mechanism of action, unique profile of activity in seizure models, and broad-spectrum clinical efficacy. The present report critically reviews several preclinical studies focused on combination therapy with levetiracetam and
Zhican Wang et al.
Endocrinology, 155(6), 2052-2063 (2014-03-20)
25-Hydroxyvitamin D3 (25OHD3) is used as a clinical biomarker for assessment of vitamin D status. Blood levels of 25OHD3 represent a balance between its formation rate and clearance by several oxidative and conjugative processes. In the present study, the identity
J Rösche et al.
Fortschritte der Neurologie-Psychiatrie, 81(1), 21-27 (2012-08-15)
Non-convulsive status epilepticus and epilepsia partialis continua are common epileptic conditions for which straightforward recommendations based on controlled randomised trials for treatment of therapy refractory courses are lacking. Therefore in these conditions sometimes antiepileptic drugs that are not approved by
Uroš Klančar et al.
AAPS PharmSciTech, 16(2), 398-406 (2014-10-22)
It is challenging to achieve mechanically robust drug-release profiles from hydrophilic matrices containing a high dose of a drug with good solubility. However, a mechanically robust drug release over prolonged period of time can be achieved, especially if the viscosity
Krzysztof Sendrowski et al.
Pharmacological reports : PR, 67(2), 326-331 (2015-02-26)
Alzheimer's disease (AD) is a common neurodegenerative disorder, in which progressive neuron loss, mainly in the hippocampus, is observed. The critical events in the pathogenesis of AD are associated with accumulation of β-amyloid (Aβ) peptides in the brain. Deposits of
Spectrofluorimetric determination of topiramate and levetiracetam as single components in tablet formulations and in human plasma and simultaneous fourth derivative synchronous fluorescence determination of their co-adminstered mixture in human plasma.
El-Yazbi AF, et al.
Journal of Fluorescence, 26(4), 1225-1238 (2016)
T M Larkin et al.
Journal of clinical pharmacy and therapeutics, 38(1), 68-70 (2012-06-26)
Levetiracetam is an anticonvulsant agent that was first approved for use in the United States in 1999 and has a maximum recommended adult dose of 3000 mg daily. It has been noted to have a relatively mild adverse effect profile
Determination of levetiracetam in human plasma by liquid chromatography/electrospray tandem mass spectrometry and its application to bioequivalence studies.
Jain DS, et al.
Rapid Communications in Mass Spectrometry, 20(17), 2539-2547 (2006)
Johan Zelano et al.
Seizure, 21(4), 233-236 (2012-02-11)
The role of new antiepileptic drugs (AED) in the treatment of status epilepticus (SE) is of interest, especially in benzodiazepine-resistant status epilepticus where phenytoin is deemed inappropriate due to allergy or comorbidity. Levetiracetam (LEV) is a new AED with few
Optimized and validated flow-injection spectrophotometric analysis of topiramate, piracetam and levetiracetam in pharmaceutical formulations
Hadad G, et al.
Acta pharmaceutica, 61(4), 377-389 (2011)
Muhammad U Farooq et al.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 66(6), 541-561 (2009-03-07)
The role of levetiracetam in different epileptic, nonepileptic, neurologic, and psychiatric disorders is discussed. Levetiracetam, an antiepileptic drug (AED), was first approved as an adjunctive therapy for the treatment of partial epilepsy in adults. It is currently being used in
Fawzi A Babtain
Clinical neuropharmacology, 35(4), 201-202 (2012-07-19)
Levetiracetam was approved for generalized and partial epilepsy in pediatric and adult population. It is also an effective antimyoclonus, but the evidence only supports its use as an adjunctive agent along with other antiepileptic drugs, such as sodium valproate, and
What is the relative value of the standard anticonvulsants: Phenytoin and fosphenytoin, phenobarbital, valproate, and levetiracetam?
Eugen Trinka
Epilepsia, 50 Suppl 12, 40-43 (2009-11-28)
Eric Dailly et al.
Therapie, 65(1), 67-70 (2010-03-09)
Levetiracetam is an anticonvulsant drug used to treat partial seizures, myoclonic seizures of juvenile myoclonic epilepsy and primary generalized tonic-clonic seizures. A review of the literature with an evidence-based medicine method highlighted parameters (age, renal failure, pregnancy, combination with other
Katherine A Lyseng-Williamson
CNS drugs, 25(10), 901-905 (2011-09-23)
Levetiracetam (Keppra®, E Keppra®) is an established second-generation antiepileptic drug (AED). Worldwide, levetiracetam is most commonly approved as adjunctive treatment of partial-onset seizures with or without secondary generalization; other approved indications include monotherapy treatment of partial-onset seizures with or without
Jingdong Chao et al.
Advances in therapy, 32(3), 270-283 (2015-03-17)
The purpose of the present study was to investigate the traceability of adverse events (AEs) for branded and generic drugs with identical nonproprietary names and to consider potential implications for the traceability of AEs for branded and biosimilar biologics. Adverse
Sabine Klein et al.
Neuropharmacology, 90, 53-62 (2014-12-03)
Despite more than 20 clinically approved antiepileptic drugs (AEDs), there remains a substantial unmet clinical need for patients with refractory (AED-resistant) epilepsy. Animal models of refractory epilepsy are needed for at least two goals; (1) better understanding of the mechanisms
Marte Helene Bjørk et al.
Epilepsia, 56(1), 28-39 (2014-12-20)
To assess incidence, prevalence, risk factors, and prognosis of peripartum depression and anxiety in a prospective study of women with epilepsy. Pregnancies in women with epilepsy (n=706) were compared to pregnancies in all women without epilepsy (n=106,511) including women with
Reversed-phase HPLC analysis of levetiracetam in tablets using monolithic and conventional C18 silica columns.
Can NO and Arli G
Journal of AOAC (Association of Official Analytical Chemists) International, 93(4), 1077-1085 (2010)
Konrad J Werhahn et al.
Epilepsia, 56(3), 450-459 (2015-02-17)
To compare the effectiveness of controlled-released carbamazepine (CR-CBZ) to levetiracetam (LEV) and to lamotrigine (LTG) in elderly patients with newly diagnosed focal epilepsy. Randomized, double-blind, parallel-group trial conducted between January 2007 and August 2011, in 47 ambulatory or hospital sites
Benjamin W Y Lo et al.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 38(3), 475-486 (2011-04-26)
New evidence suggests that levetiracetam may be as effective as traditional agents, with better safety profile. To synthesize evidence regarding efficacy and tolerability of levetiracetam as first line, adjunctive or prophylactic antiepileptic agent. Study Selection & Data Extraction: Eligible studies
1/2